PHP
MDGL icon

Parkman Healthcare Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Parkman Healthcare Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,840
Closed -$6.26M – 102
2023
Q1 		$6.26M Buy
25,840
+18,499
+252% +$5.04M 1.36% 30
2022
Q4 		$2.13M Sell
7,341
-14,249
-66% -$1.39M 0.57% 56
2022
Q3 		$1.4M Buy
21,590
+254
+1% +$17.6K 0.4% 66
2022
Q2 		$1.53M Buy
21,336
+1,106
+5% +$81.3K 0.56% 49
2022
Q1 		$1.99M Sell
20,230
-8,440
-29% -$712K 0.58% 47
2021
Q4 		$2.43M Sell
28,670
-2,723
-9% -$224K 0.54% 50
2021
Q3 		$2.5M Sell
31,393
-5,000
-14% -$432K 0.63% 49
2021
Q2 		$3.54M Sell
36,393
-3,328
-8% -$394K 0.78% 41
2021
Q1 		$4.65M Buy
39,721
+26,745
+206% +$3.12M 1.08% 31
2020
Q4 		$1.44M Sell
12,976
-5,235
-29% -$640K 0.37% 67
2020
Q3 		$2.16M Sell
18,211
-31,789
-64% -$3.45M 0.57% 56
2020
Q2 		$5.66M Buy
50,000
+20,000
+67% +$1.97M 1.6% 27
2020
Q1 		$2M Buy
+30,000
New +$2.5M 0.93% 36

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Parkman Healthcare Partners's MDGL Position: Q2 2023 in Review

Parkman Healthcare Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2023, closing a stake of 25,840 shares — an estimated $6.26M sold.

Parkman Healthcare Partners first reported a position in MDGL in Q1 2020 and held it in 13 quarters. The position peaked at $6.26M in Q1 2023. 208 funds tracked by Wall St. Rank hold MDGL as of Q2 2023.

  • Parkman Healthcare Partners reported no remaining Madrigal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 25,840 Madrigal Pharmaceuticals shares in Q2 2023, an estimated $6.26M.
  • Parkman Healthcare Partners first reported a position in Madrigal Pharmaceuticals in Q1 2020 and held it in 13 quarters.
  • Parkman Healthcare Partners's Madrigal Pharmaceuticals position peaked at $6.26M in Q1 2023.
  • 208 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2023.

Based on Parkman Healthcare Partners's 13F filing for Q2 2023, filed 11 Aug 2023.